文献速递心境障碍焦虑、强迫与应激相关障碍精神分裂症与精神病性障碍

大麻素类药物治疗精神障碍及精神症状的系统综述与荟萃分析

Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.
PubMed 文献 · Lancet Psychiatry · 2019-10-28

该系统综述与荟萃分析检索1980年至2018年间的文献,纳入83项研究(40项随机对照试验,n=3067),评估医用大麻素对抑郁、焦虑、ADHD、Tourette综合征、PTSD和精神病的效果与安全性。结果显示,除合并其他躯体疾病者使用药用THC(含或不含CBD)焦虑症状有小幅改善(证据质量极低)外,大麻素对上述精神障碍的主要结局均无显著获益,且不良事件和因不良事件退出风险增加。

要点

  • 药用THC(含或不含CBD)对合并其他躯体疾病者的焦虑症状有小幅改善,但证据质量极低。
  • 药用THC(含或不含CBD)在单项研究中加重精神病阴性症状。
  • 与安慰剂相比,大麻素类药物的不良事件发生率和因不良事件退出率均显著增加。

核心结论

  • 证据稀缺,不足以提示大麻素类可改善抑郁、焦虑、ADHD、Tourette综合征、PTSD或精神病。
  • 极低质量证据提示药用THC(含或不含CBD)对合并其他躯体疾病者的焦虑症状有小幅改善。
  • 证据不足以在监管框架内为使用大麻素类治疗精神障碍提供指导。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase、PsycINFO、Cochrane图书馆等数据库及临床试验注册平台。
  • 纳入1980年1月1日至2018年4月30日发表的任何类型研究(含随机对照试验和观察性研究),对象为≥18岁成人。
  • 共纳入83项符合条件的研究,其中40项为随机对照试验(n=3067)。

主要发现

  • 药用THC(含或不含CBD)对受评估精神障碍的其他主要结局均无显著影响。

关键数值与推荐

  • 主要结局为精神障碍的缓解和症状变化,安全性结局包括不良事件和退出。
  • 随机对照试验证据通过随机效应荟萃分析合成,二分类结局用OR,连续结局用SMD。
  • 证据质量采用Cochrane偏倚风险工具和GRADE方法评估。

临床怎么用

  • 目前证据不支持使用大麻素类药物治疗抑郁、焦虑、ADHD、Tourette综合征、PTSD或精神病。
  • 对合并慢性非癌痛或多发性硬化等躯体疾病且伴焦虑症状者,药用THC(含或不含CBD)可能有小幅改善,但证据质量极低且需权衡不良事件风险。
  • 使用大麻素类时需警惕不良事件增加及因不良事件停药的风险。

局限性

  • 随机对照试验数量有限,尤其涉及药用CBD和医用大麻的研究很少。
  • 部分分析证据质量极低(如焦虑症状改善)。
  • 纳入研究类型多样(含观察性研究),部分结局仅基于单项研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Medicinal cannabinoids, including medicinal cannabis and pharmaceutical cannabinoids and their synthetic derivatives, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), have been suggested to have a therapeutic role in certain mental disorders. We analysed the available evidence to ascertain the effectiveness and safety of all types of medicinal cannabinoids in treating symptoms of various mental disorders. METHODS: For this systematic review and meta-analysis we searched MEDLINE, Embase, PsycINFO, the Cochrane Central Register of Controlled Clinical Trials, and the Cochrane Database of Systematic Reviews for studies published between Jan 1, 1980, and April 30, 2018. We also searched for unpublished or ongoing studies on ClinicalTrials.gov, the EU Clinical Trials Register, and the Australian and New Zealand Clinical Trials Registry. We considered all studies examining any type and formulation of a medicinal cannabinoid in adults (≥18 years) for treating depression, anxiety, attention-deficit hyperactivity disorder (ADHD), Tourette syndrome, post-traumatic stress disorder, or psychosis, either as the primary condition or secondary to other medical conditions. We placed no restrictions on language, publication status, or study type (ie, both experimental and observational study designs were included). Primary outcomes were remission from and changes in symptoms of these mental disorders. The safety of medicinal cannabinoids for these mental disorders was also examined. Evidence from randomised controlled trials was synthesised as odds ratios (ORs) for disorder remission, adverse events, and withdrawals and as standardised mean differences (SMDs) for change in symptoms, via random-effects meta-analyses. The quality of the evidence was assessed with the Cochrane risk of bias tool and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. This study is registered with PROSPERO (CRD42017059372, CRD42017059373, CRD42017059376, CRD42017064996, and CRD42018102977). FINDINGS: 83 eligible studies (40 randomised controlled trials, n=3067) were included: 42 for depression (23 randomised controlled trials; n=2551), 31 for anxiety (17 randomised controlled trials; n=605), eight for Tourette syndrome (two randomised controlled trials; n=36), three for ADHD (one randomised controlled trial; n=30), 12 for post-traumatic stress disorder (one randomised controlled trial; n=10), and 11 for psychosis (six randomised controlled trials; n=281). Pharmaceutical THC (with or without CBD) improved anxiety symptoms among individuals with other medical conditions (primarily chronic non-cancer pain and multiple sclerosis; SMD -0·25 [95% CI -0·49 to -0·01]; seven studies; n=252), although the evidence GRADE was very low. Pharmaceutical THC (with or without CBD) worsened negative symptoms of psychosis in a single study (SMD 0·36 [95% CI 0·10 to 0·62]; n=24). Pharmaceutical THC (with or without CBD) did not significantly affect any other primary outcomes for the mental disorders examined but did increase the number of people who had adverse events (OR 1·99 [95% CI 1·20 to 3·29]; ten studies; n=1495) and withdrawals due to adverse events (2·78 [1·59 to 4·86]; 11 studies; n=1621) compared with placebo across all mental disorders examined. Few randomised controlled trials examined the role of pharmaceutical CBD or medicinal cannabis. INTERPRETATION: There is scarce evidence to suggest that cannabinoids improve depressive disorders and symptoms, anxiety disorders, attention-deficit hyperactivity disorder, Tourette syndrome, post-traumatic stress disorder, or psychosis. There is very low quality evidence that pharmaceutical THC (with or without CBD) leads to a small improvement in symptoms of anxiety among individuals with other medical conditions. There remains insufficient evidence to provide guidance on the use of cannabinoids for treating mental disorders within a regulatory framework. Further high-quality studies directly examining the effect of cannabinoids on treating mental disorders are needed. FUNDING: Therapeutic Goods Administration, Australia; Commonwealth Department of Health, Australia; Australian National Health and Medical Research Council; and US National Institutes of Health.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019. PMID: 31672337. doi:10.1016/S2215-0366(19)30401-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。